412 related articles for article (PubMed ID: 24319218)
1. Consequences and management of iron overload in sickle cell disease.
Porter J; Garbowski M
Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
[TBL] [Abstract][Full Text] [Related]
2. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
3. Iron-chelating therapy for transfusional iron overload.
Musallam KM; Taher AT
N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
[No Abstract] [Full Text] [Related]
4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and treatment of transfusional iron overload in children.
Ware HM; Kwiatkowski JL
Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
[TBL] [Abstract][Full Text] [Related]
6. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
Aubart M; Ou P; Elie C; Canniffe C; Kutty S; Delos V; Graffigne C; de Montalembert M; Brousse V
J Pediatr Hematol Oncol; 2016 Oct; 38(7):497-502. PubMed ID: 27548334
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease.
Porter JB
Hemoglobin; 2009; 33 Suppl 1():S37-45. PubMed ID: 20001631
[TBL] [Abstract][Full Text] [Related]
9. Iron-chelating therapy for transfusional iron overload.
Taccone-Gallucci M; Manca-di-Villahermosa S; Noce A
N Engl J Med; 2011 Apr; 364(15):1476-7; author reply 1477. PubMed ID: 21488786
[No Abstract] [Full Text] [Related]
10. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Porter JB; Shah FT
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
[TBL] [Abstract][Full Text] [Related]
11. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
[TBL] [Abstract][Full Text] [Related]
12. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
[TBL] [Abstract][Full Text] [Related]
13. Iron-chelating therapy for transfusional iron overload.
Solomon LR
N Engl J Med; 2011 Apr; 364(15):1475-6; author reply 1477. PubMed ID: 21488788
[No Abstract] [Full Text] [Related]
14. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
[TBL] [Abstract][Full Text] [Related]
17. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
[TBL] [Abstract][Full Text] [Related]
18. Transfusion therapy for sickle cell disease: a balancing act.
Chou ST
Hematology Am Soc Hematol Educ Program; 2013; 2013():439-46. PubMed ID: 24319217
[TBL] [Abstract][Full Text] [Related]
19. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
Stanley HM; Friedman DF; Webb J; Kwiatkowski JL
Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
[TBL] [Abstract][Full Text] [Related]
20. Iron overload in adults with sickle cell disease who have received intermittent red blood cell transfusions.
Pack-Mabien A; Brown B; Herbert DE; Haynes J
J Am Assoc Nurse Pract; 2015 Oct; 27(10):591-6. PubMed ID: 25711464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]